In turn, a significantly higher risk of non-response after the 4th cycle of chemotherapy was observed in patients with elevated CRP (OR = 6.70), those with the presence of t(11.14)/CCND1 translocation (a trend toward significance; OR = 6.42) and those who were carriers of the TT genotype of the KIAA1524 gene (OR = 20.20).
← all excerpts
The TT Genotype of the <i>KIAA1524 rs2278911</i> Polymorphism Is Associated with Poor Prognosis in Multiple Myeloma.
1
—
—